Beta-Adrenergic Receptors of S49 Lymphoma Cells
Beta-Adrenergic Receptors of S49 Lymphoma Cells
批准号:
6865429
负责人:
PAUL A INSEL
金额:
$32.09万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-03-01 至 2007-02-28
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose to continue our long-standing
studies in the B-adrenergic receptor (BetaAR) signalling pathway of S49 lymphoma
cells. These cells provide a unique model system in which to characterize the
role of particular components in this pathway in which BAR increase cellular
levels of cyclic AMP (cAMP), activate protein kinase A (PKA), and trigger
events that ultimately lead to growth arrest and death of the cells. Feedback
regulation of signalling occurs via a G protein receptor kinase (GRK), as well
as PKA. Our preliminary studies indicate that cAMP-mediated cell death of S49
cells occurs via an apoptotic mechanism that requires PKA. Moreover, other
recent findings implicate a key role of PKA desensitization of the BAR pathway.
We propose to utilize wild-type S49 cells and known variants of S49 cells with
lesions in the BAR response pathway (including an S49 cell line which does not
undergo apoptosis in spite of apparently normal "upstream" signalling
components) to define the role of cAMP generation/PKA activation and mechanisms
involved in apoptosis and in addition the contribution of G protein receptor
kinase and PKA to ongoing feedback regulation of events involved in cAMP
formation and action. Based on other preliminary results, we will also conduct
studies of GRK and PKA using Chinese hamster ovary (CHO) cells, both wild-type
and PKA-absent CHO cells. Data in the CHO system regarding receptor
desensitization should complement studies in the S49 cell system. By using a
combined approach that involves techniques of cell and molecular biology,
biochemistry, and pharmacology, we should obtain new information regarding BAR
signalling. Since BAR play an important physiologic role in many organ systems,
in particular the cardiovascular, renal, and pulmonary systems, and BAR are
targets of drug therapy in many clinically important disorders (e.g.,
hypertension, asthma, myocardial ischemia, chronic obstructive pulmonary
disease, congestive heart failure), our results may provide useful new insights
regarding both physiological regulation as well as drug therapy with agents
that stimulate or block BetaAR signalling. Moreover, the results should prove
applicable to the many other hormone and neurotransmitter receptors that link
to G proteins.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/ijc.25785
发表时间:
2011-09-01
期刊:
INTERNATIONAL JOURNAL OF CANCER
影响因子:
6.4
作者:
[Zhang, Lingzhi, Murray, Fiona, Rassenti, Laura Z., Pu, Minya, Kelly, Colleen, Kanter, Joan R., Greaves, Andrew, Messer, Karen, Kipps, Thomas J., Insel, Paul A.]
通讯作者:
Insel, Paul A.
DOI:
10.1038/jhg.2011.80
发表时间:
2011-09
期刊:
Journal of human genetics
影响因子:
3.5
作者:
[]
通讯作者:
DOI:
10.1126/scisignal.3104re1
发表时间:
2010-01-12
期刊:
Science signaling
影响因子:
7.3
作者:
[Corriden R, Insel PA]
通讯作者:
Insel PA
Cytotoxic T lymphocyte antigen-2 alpha induces apoptosis of murine T-lymphoma cells and cardiac fibroblasts and is regulated by cAMP/PKA.
细胞毒性 T 淋巴细胞抗原 2 α 诱导小鼠 T 淋巴瘤细胞和心脏成纤维细胞凋亡,并受 cAMP/PKA 调节。
DOI:
10.1016/j.cellsig.2011.05.014
发表时间:
2011
期刊:
Cellular signalling
影响因子:
4.8
作者:
[Zhang,Lingzhi, Yun,Hongruo, Murray,Fiona, Lu,Ruilin, Wang,Lin, Hook,Vivian, Insel,PaulA]
通讯作者:
Insel,PaulA
Caveolin-3 and cardiac fibrosis
-
批准号:9318093
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2017
-
负责人:PAUL A INSEL
-
依托单位:
GPCRs: novel targets in cancer-associated fibroblasts
-
批准号:8773037
-
项目类别:
-
资助金额:$20.23万
-
财政年份:2014
-
负责人:PAUL A INSEL
-
依托单位:
2011 Molecular Pharmacology GRC and GRS
-
批准号:8059911
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2011
-
负责人:PAUL A INSEL
-
依托单位:
2009 Molecular Pharmacology Gordon Research Conference
-
批准号:7672009
-
项目类别:
-
资助金额:$4.35万
-
财政年份:2009
-
负责人:PAUL A INSEL
-
依托单位:
Adenylyl Cyclase and Cardiac Interstitium
-
批准号:7482977
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2007
-
负责人:PAUL A INSEL
-
依托单位:
Adenylyl Cyclase and Cardiac Interstitium
-
批准号:7217649
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2006
-
负责人:PAUL A INSEL
-
依托单位:
PURINERGIC RECEPTOR RESEARCH
-
批准号:7358044
-
项目类别:
-
资助金额:$1.22万
-
财政年份:2006
-
负责人:PAUL A INSEL
-
依托单位:
PURINERGIC RECEPTOR RESEARCH
-
批准号:7181339
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2005
-
负责人:PAUL A INSEL
-
依托单位:
Adrenergic and Purinergic Regulation of Target Cells
-
批准号:6950048
-
项目类别:
-
资助金额:$33.0万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
Adrenergic and Purinergic Regulation of Target Cells
-
批准号:6776563
-
项目类别:
-
资助金额:$32.92万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
Adrenergic and Purinergic Regulation of Target Cells
-
批准号:7116276
-
项目类别:
-
资助金额:$32.28万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
Adrenergic and Purinergic Regulation of Target Cells
-
批准号:7730124
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
PURINERGIC RECEPTOR RESEARCH
-
批准号:6975362
-
项目类别:
-
资助金额:$1.29万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
Adrenergic and Purinergic Regulation of Target Cells
-
批准号:7279299
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
GPCRs: Evolving Concepts and Drug Discovery
-
批准号:6748021
-
项目类别:
-
资助金额:$2.2万
-
财政年份:2004
-
负责人:PAUL A INSEL
-
依托单位:
Adenylyl cyclase regulation and heart failure
-
批准号:6564966
-
项目类别:
-
资助金额:$13.92万
-
财政年份:2002
-
负责人:PAUL A INSEL
-
依托单位:
Core--Receptors, signal transduction, sympathochromaffin biochemistry
-
批准号:6652854
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2002
-
负责人:PAUL A INSEL
-
依托单位:
CORE--ADRENERGIC RECEPTORS AND INTRACELLULAR SIGNALING
-
批准号:6610365
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2002
-
负责人:PAUL A INSEL
-
依托单位:
CORE--ADRENERGIC RECEPTORS AND INTRACELLULAR SIGNALING
-
批准号:6613940
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2002
-
负责人:PAUL A INSEL
-
依托单位:
Beta-Adrenergic Receptors of S49 Lymphoma Cells
-
批准号:6623903
-
项目类别:
-
资助金额:$31.91万
-
财政年份:2002
-
负责人:PAUL A INSEL
-
依托单位:
海外基金